SAR-444200

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameSAR-444200
Drug Alias NameSAR-444200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionGlypican-3 inhibitorsT-cell receptor modulators
TargetsGlypican-3T-cell receptor
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis Recherche & DeveloppementSanofi (China) Investment Co Ltd
Inactive CompaniesSanofi
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A